Overview of Eli Lilly's Stock Rating#
Morgan Stanley has reaffirmed its Overweight rating on Eli Lilly (NYSE: LLY) stock, setting a price target of $1,327. Currently, Eli Lilly's stock trades at $901.65, and analysts believe it is undervalued based on its estimated fair value. The company has a market capitalization of $805 billion, indicating its significant presence in the pharmaceutical industry.
Medicare Coverage and Future Sales Projections#
Recent discussions from UnitedHealth and CVS have raised concerns about the future of Medicare coverage under the CMS BALANCE program, which is set to broaden access to GLP-1 medications for obesity by 2027. This expansion is crucial for Eli Lilly's growth, particularly for its obesity treatment, Zepbound. Morgan Stanley projects that sales for Zepbound and another drug, Foundayo, could reach around $31 billion by 2027, with combined sales expected to rise to approximately $45 billion by 2030.
Upcoming Medicare Changes#
Under the BALANCE Model, Eli Lilly's Zepbound, Mounjaro, and Foundayo will be accessible through Medicare Part D plans starting January 1, 2027. However, beneficiaries may gain access to these medications as early as July 2026 through a short-term program. A report from Kaiser indicates that if 80% of Part D sponsors do not participate in BALANCE, the program may not proceed, with a decision expected by April 30, 2026.
Recent Developments and Market Reactions#
Eli Lilly recently announced its acquisition of Kelonia Therapeutics for $3.25 billion, potentially rising to $7 billion with milestone payments. This move has prompted positive ratings from UBS and RBC Capital, who have set price targets of $1,250. Meanwhile, shares of Eli Lilly and Novo Nordisk faced declines after CVS Health opted out of the Medicare obesity drug coverage model, although CVS's stock rose following the announcement. These events illustrate the evolving landscape in the pharmaceutical sector, particularly regarding obesity treatments and strategic acquisitions.